HCK Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, offering a pooled loss-of-function model for the HCK gene. This product provides a genetically disrupted HCK locus without clonal selection, enabling the study of HCK-dependent signaling in a heterogeneous population that mirrors typical experimental cultures. The polyclonal format minimizes biases from single-cell cloning and supports robust, reproducible assays where population-level responses are critical. HCK, a member of the Src family of non-receptor tyrosine kinases, is a key mediator of signals from integrins and immunoreceptors, and its disruption allows researchers to dissect its function in epithelial cell biology.
HeLa cells, the host for this knockout model, are an immortalized epithelial cell line originally derived from a cervical adenocarcinoma. They harbor integrated human papillomavirus type 18 (HPV18) sequences, and the viral E6 oncoprotein targets p53 for degradation, contributing to genomic instability and continuous proliferation. This background makes HeLa a versatile platform for studying oncogenic signaling, viral interactions, and fundamental cell biology. As a widely used model in cancer research and virology, HeLa cells provide a well-characterized context for evaluating the impact of HCK loss on adhesion, migration, and signal transduction.
HCK functions as a non-receptor tyrosine kinase that transduces signals from a variety of cell surface receptors. Upstream, HCK is activated by integrin receptors, Fc receptors, and cytokine receptors such as IL-3R and GM-CSFR, as well as growth factor receptors; its activity is modulated by the Src family kinases Lyn and Fyn and negatively regulated by Csk. Once activated, HCK phosphorylates downstream targets including BCR-ABL, STAT5, PI3K, Akt, ERK, paxillin, cortactin, Vav, and Btk. HCK interacts with adaptor and scaffold molecules such as p130Cas, FAK, Cbl, the PI3K p85 subunit, SHIP, and SHP-1. In the context of integrin signaling, HCK is a critical node in the pathway linking integrin ??IIb??3 engagement to FAK, Src, p130Cas, Crk, DOCK180, and Rac1, driving cytoskeletal reorganization. In immune-receptor pathways, it functions downstream of Fc??R, cooperating with Syk, Btk, PLC??2, and Vav to activate Rac1, thereby regulating phagocytosis and cell adhesion.
In HeLa epithelial cells, disruption of HCK is predicted to impair integrin-mediated adhesion and migration, potentially attenuating the invasive phenotype often associated with this cervical adenocarcinoma model. Although HCK is predominantly expressed in hematopoietic lineages, its aberrant activation in non-hematopoietic tumors can contribute to malignancy. Therefore, this polyclonal knockout population provides a valuable tool for dissecting HCK’s contribution to epithelial cell motility, cytoskeletal dynamics, and signaling crosstalk with oncogenic drivers, such as HPV oncoproteins, within a well-characterized cancer model. This model allows the study of non-hematopoietic Src kinase functions and the evaluation of HCK as a potential therapeutic target in epithelial cancers.
Researchers can employ this HCK knockout HeLa polyclonal population in a range of functional assays. Western blotting and phospho-kinase profiling can verify HCK loss and map compensatory signaling changes, while scratch wound and transwell invasion assays quantify alterations in migration and invasiveness. Cell adhesion assays and immunofluorescence for focal adhesion proteins like paxillin enable detailed study of adhesion dynamics, and integrin activation flow cytometry can assess receptor status. Additionally, drug sensitivity testing with Src family kinase inhibitors provides a platform for target validation and therapeutic screening. For further technical details or to discuss custom applications, please contact Ascent Research.
